Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control ...

(NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 (catalytic domain) is designed to maximize ...

TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct ...

Sanofi and Teva are closing the gap with positive data on their own anti-TL1A antibody duvakitug. In the phase 2b RELIEVE UCCD trial, duvakitug met the mark in patients with ulcerative colitis (UC ...

Education of doctors at all levels including gastroenterologists on the new possibilities of the laboratory immunodiagnosis of autoimmune liver diseases, so that tests would be appropriately ...

If a company has positive cash flow, the company's liquid assets are increasing. Net income is the profit a company has earned, or the income that's remaining after all expenses have been deducted.

The study presents a potential alternative to adeno-associated virus (AAV)-mediated gene therapy, addressing the exclusion of patients with preexisting anti-AAV antibodies. Severe hemophilia A is ...

[36] SUMOs are linked covalently to Sp100 and PML, and autoantibodies against SUMOs were exclusively detected in a proportion of anti-MND-positive ... of antinuclear antibodies with unfavorable ...